11,319 Shares in Bellicum Pharmaceuticals, Inc. (BLCM) Purchased by Voya Investment Management LLC

Voya Investment Management LLC bought a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,319 shares of the biopharmaceutical company’s stock, valued at approximately $132,000.

Several other hedge funds have also modified their holdings of BLCM. Ronald Blue & Co. LLC purchased a new position in shares of Bellicum Pharmaceuticals in the 2nd quarter valued at $117,000. Clear Harbor Asset Management LLC purchased a new position in shares of Bellicum Pharmaceuticals in the 2nd quarter valued at $118,000. American International Group Inc. raised its stake in shares of Bellicum Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 852 shares during the period. Nationwide Fund Advisors raised its stake in shares of Bellicum Pharmaceuticals by 30.4% in the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares during the period. Finally, ProShare Advisors LLC raised its stake in shares of Bellicum Pharmaceuticals by 14.9% in the 2nd quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 2,513 shares during the period. 54.78% of the stock is currently owned by institutional investors and hedge funds.

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at $9.99 on Friday. Bellicum Pharmaceuticals, Inc. has a fifty-two week low of $7.41 and a fifty-two week high of $20.78. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.08 and a quick ratio of 6.08.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.03 million. Bellicum Pharmaceuticals had a negative net margin of 18,596.03% and a negative return on equity of 83.23%. The business’s revenue was up 18.2% on a year-over-year basis. During the same period last year, the business earned ($0.66) EPS. research analysts expect that Bellicum Pharmaceuticals, Inc. will post -2.94 earnings per share for the current fiscal year.

WARNING: “11,319 Shares in Bellicum Pharmaceuticals, Inc. (BLCM) Purchased by Voya Investment Management LLC” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/11/24/11319-shares-in-bellicum-pharmaceuticals-inc-blcm-purchased-by-voya-investment-management-llc.html.

BLCM has been the topic of a number of research reports. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Raymond James Financial, Inc. set a $18.00 target price on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 target price (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research note on Thursday, August 10th. ValuEngine downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. Finally, Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Bellicum Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $26.20.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply